FDA Approves New PET Imaging Agent for Recurring Prostate Cancer

May 31, 2016

Today Blue Earth Diagnostics announced that the FDA has approved AxuminTM (F-18-labeled fluciclovine injection) for detecting biochemical recurrence of prostate cancer. It is the first FDA-approved F-18-labeled PET imaging agent for use in patients with suspected recurrent prostate cancer.

FDA approves new diagnostic imaging agent to detect recurrent prostate cancer

Blue Earth Diagnostics